



NORWAY

(19) NO
(51) Int Cl.
A61K 47/48 (2006.01)

Norwegian Industrial Property Office

(21) Translation Published 2015.06.29

(80) Date of The European Patent Office Publication of the Granted Patent 2015.01.14

(86) European Application Nr. 08742082.4

(86) European Filing Date 2008.03.12

(87) The European Application's Publication Date 2009.12.23

(30) Priority 2007.03.12, US, 906387 P

(84) Designated Contracting States: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

Designated Extension States: AL BA MK RS

(73) Proprietor Nektar Therapeutics, 455 Mission Bay Boulevard South Suite 100, San Francisco CA 94158, US-USA

(72) Inventor RIGGS-SAUTHIER, Jennifer, 7917 Smoke Rise Road, Huntsville, AL 35802, US-USA
DENG, Bo-liang, 222 Kyser Boulevard Apt. 56, Madison, AL 35758, US-USA
RILEY, Timothy, Andrew, 211 Morningwalk Lane, Huntsville, AL 35824, US-USA

(74) Agent or Attorney Tandbergs Patentkontor AS, Postboks 1570 Vika, 0118 OSLO, Norge


(54) Title **OLIGOMER-OPIOID AGONIST CONJUGATES**

(56) References Cited:
WO-A-03/032990
WO-A-2004/039317
WO-A-2004/082620
WO-A-2005/058367
WO-A-2008/036980
FUKUDA KAZUHIKO ET AL: "Partial agonistic activity of naloxone on the opioid receptors expressed from complementary deoxyribonucleic acids in Chinese hamster ovary cells" ANESTHESIA AND ANALGESIA, vol. 87, no. 2, August 1998 (1998-08), pages 450-455, XP002488162 ISSN: 0003-2999
OKUDA T ET AL: "PROLONGED ANTINOCICEPTIVE EFFECT AFTER EPIDURAL INJECTION OF POLYETHYLENEGLYCOL-MORPHINE COMPOSITES IN RATS" MASUI - JAPANESE JOURNAL OF ANESTHESIOLOGY, TOKYO, JP, vol. 45, no. 5, 1 January 1996 (1996-01-01), pages 571-575, XP008035141 ISSN: 0021-4892
EREZ M ET AL: "Narcotic antagonistic potency of bivalent ligands which contain beta-naltrexamine. Evidence for bridging between proximal recognition sites" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 25, no. 7, 1 July 1982 (1982-07-01), pages 847-849, XP002334914 ISSN: 0022-2623

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

- 5 **1.** En opioidagonist-forbindelse som omfatter en rest av en opioidagonist kovalent bundet til en vannløselig, ikke-peptidoligomer, hvor forbindelsen har formelen:



hvor:

R¹ er metyl;

10 R² er OH;

R³ er metyl;

R⁴ er hydrogen;

Y¹ er oksygen; og

n er et helt tall fra 1 til 30.

15

2. Forbindelse ifølge krav 1, karakterisert ved at n er et helt tall fra 1 til 10.

3. Forbindelse ifølge krav 1, karakterisert ved at n er 6.

20 **4.** En sammensetning omfattende en forbindelse ifølge hvilket som helst av kravene 1 til 3, og eventuelt en farmasøytisk akseptabel eksipiens.

5. En forbindelse ifølge ethvert av kravene 1 til 3 eller et preparat ifølge krav 4, for bruk i terapi.